Given these constraints, we decided to investigate the role of inherited genetic polymorphisms in GIST development by conducting a case-only analysis of the association between tumor mutation type (mutations in KIT exon 11, KIT exon 9, PDGFRA, or wild type) and 225 variants in 39 candidate genes using tumor and blood samples collected during a phase III clinical trial of adjuvant imatinib [29]. This evidence concerns the gene KIT and gastrointestinal stromal tumor.